Key points are not available for this paper at this time.
How does once-weekly subcutaneous tirzepatide affect maintenance of weight loss in individuals with obesity or overweight?
Aronne et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: